AVIR

Business Context and Reporting Period

Atea Pharmaceuticals, Inc. (AVIR) is a late-stage clinical biopharmaceutical company focused on developing oral antivirals for serious viral diseases. The filing covers the fiscal year ended December 31, 2025. The company has no approved products and has not generated commercial revenue since inception. Its primary focus is the development of a regimen of bemnifosbuvir and ruzasvir for Hepatitis C Virus (HCV) and AT-587 for Hepatitis E Virus (HEV).

Key Financial Metrics

Note: The company reported an income tax benefit of $6.2 million in 2025 compared to an expense of $0.9 million in 2024, primarily due to the lapse of statutes of limitations on previously unrecognized tax benefits.

Material Changes vs. Prior Period

• Operating Expenses: Total operating expenses decreased by $12.1 million (6.3%) year-over-year. This reduction was driven primarily by a $16.0 million decrease in G&A expenses, attributed to lower stock-based compensation and a 25% workforce reduction in Q1 2025.
• R&D Expenses: R&D expenses increased by $3.9 million. This increase was due to higher external spend for the HCV Phase 3 clinical program (including comparator drug purchases) and a $5.0 million milestone payment to Merck for the initiation of the C-BEYOND trial. These increases were partially offset by the conclusion of the COVID-19 program and lower internal R&D costs.
• Share Repurchase: The company completed a $25.0 million share repurchase program in 2025, retiring 7,673,792 shares. This resulted in $25.7 million of net cash used in financing activities.
• Liquidity: Cash and investments decreased by approximately $153 million, reflecting operating cash burn and share repurchases, though the company maintains a runway through 2027.

Guidance, Outlook, and Risks

Outlook and Milestones

• HCV Program: The global Phase 3 program (C-BEYOND and C-FORWARD) is ongoing. C-BEYOND is fully enrolled with over 880 patients; topline results are expected mid-2026. C-FORWARD enrollment is progressing; topline results are expected year-end 2026. An NDA submission to the FDA is targeted for March 2027 pending successful results.
• HEV Program: AT-587 is in preclinical development. A first-in-human Phase 1 study is anticipated to begin in mid-2026.
• Financial Runway: Management believes current resources ($301.8 million) are sufficient to fund operations through 2027, covering Phase 3 completion, NDA preparation, and initial commercial supply manufacturing.

Risks and Contingencies

• Capital Requirements: The company expects to incur significant losses for the foreseeable future and may require additional financing. Failure to secure capital could force delays or termination of development programs.
• Intellectual Property: Gilead Sciences holds patents (e.g., '361 and '529) that purport to cover bemnifosbuvir. Atea believes these are invalid but faces litigation risk that could block commercialization or require licensing.
• Manufacturing Dependence: The company relies on third-party manufacturers, including a sole supplier in China for the active pharmaceutical ingredient of ruzasvir. Supply chain disruptions or trade policy changes pose significant risks.
• Regulatory Uncertainty: Approval is not guaranteed. The company previously discontinued its COVID-19 program after the Phase 3 SUNRISE-3 trial failed to meet its primary endpoint in 2024.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $301.8 million cash balance to fund operations through 2027 given the high burn rate of Phase 3 trials.
• IP Litigation Status: Monitor the status of the Post-Grant Review petition against Gilead's '361 patent and any potential infringement lawsuits regarding the '529 patent.
• Phase 3 Enrollment: Track enrollment progress in the C-FORWARD trial and the timeline for topline data release in 2026.
• Merck Milestones: Confirm the timing and payment of the next $10.0 million milestone to Merck, contingent on FDA acceptance of the NDA.
• Supply Chain Resilience: Assess the risks associated with the sole-source supplier in China for ruzasvir and the impact of potential trade tariffs or geopolitical instability.